Takeda Confirms Significant Hypoglycemic Effect In Novel Diabetes Drug Fasiglifam
This article was originally published in PharmAsia News
Executive Summary
Takeda announced significant hypoglycemic effect of its new type 2 diabetes drug fasiglifam in domestic Phase III trials on diabetes at the Japan Diabetes Society Meeting.